ITC blocks Chinese biotech imports in favor of Ventria

By Jasmin Jackson (September 13, 2022, 8:12 p.m. EDT) – The United States International Trade Commission has blocked four biotech companies from importing a vaccine ingredient from China that infringes a cell culture patent held by Ventria Bioscience.

The ITC agreed in a notice Tuesday to issue a limited exclusion order against Wuhan Healthgen Biotechnology Corp. and three other importers of recombinant human serum albumin, or rHSA, which Ventria Bioscience Inc. claims infringed two of its cell culture patents. The commission’s opinion backs up an administrative law judge’s April ruling that the disputed imports – which prompted the Kansas attorney general to raise concerns about “Chinese economic espionage” in a letter. ..

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!



About Author

Comments are closed.